Examining Sex Differences in Markers of Cognition and Neurodegeneration in Autosomal Dominant Alzheimer's Disease: Preliminary Findings from the Colombian Alzheimer's Prevention Initiative Biomarker Study.
Alzheimer’s disease
atrophy
cognition
familial Alzheimer’s disease
memory
sex
Journal
Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863
Informations de publication
Date de publication:
2020
2020
Historique:
pubmed:
15
9
2020
medline:
11
9
2021
entrez:
14
9
2020
Statut:
ppublish
Résumé
Growing evidence suggests that there may be a sex-specific biological risk for Alzheimer's disease (AD). Individuals with autosomal dominant AD due to a mutation (E280A) in Presenilin-1 (PSEN1) are genetically determined to develop early-onset dementia and thus, have few age-related risk factors for AD that are known to vary by sex (i.e., cardiovascular disease, menopause, life expectancy). Investigate sex differences in markers of cognition and neurodegeneration in autosomal dominant AD. We conducted a retrospective study in 19 cognitively-unimpaired PSEN1 mutation carriers (age range 20-44; 11 females), 11 symptomatic carriers (age range 42-56; 8 females), and 23 matched non-carriers family members (age range 20-50; 13 females). We examined hippocampal volume ratio, CERAD Total Score, and CERAD Word List (i.e., Learning, Delayed Recall, and Recognition). Mann-Whitney U tests, Spearman correlations and regression models were conducted. There were no differential associations between age, CERAD Total Score, CERAD Word List-Learning, Delayed Recall, Recognition, and hippocampal volume ratio in male and female carriers and non-carriers. Cognitively-unimpaired female carriers showed better CERAD Total scores and CERAD Word List-Learning than cognitively-unimpaired male carriers, despite having similar hippocampal volume ratios. The interaction of sex and hippocampal volume ratio did not predict cognitive performance across groups. Our preliminary findings suggest that cognitively-unimpaired female carriers showed a verbal memory reserve, and as disease progresses, female carriers did not exhibit a cognitive susceptibility to AD-related neurodegeneration. Future studies with larger samples of autosomal dominant AD are warranted to further understand sex differences in AD-related clinical and pathological markers.
Sections du résumé
BACKGROUND
Growing evidence suggests that there may be a sex-specific biological risk for Alzheimer's disease (AD). Individuals with autosomal dominant AD due to a mutation (E280A) in Presenilin-1 (PSEN1) are genetically determined to develop early-onset dementia and thus, have few age-related risk factors for AD that are known to vary by sex (i.e., cardiovascular disease, menopause, life expectancy).
OBJECTIVE
Investigate sex differences in markers of cognition and neurodegeneration in autosomal dominant AD.
METHODS
We conducted a retrospective study in 19 cognitively-unimpaired PSEN1 mutation carriers (age range 20-44; 11 females), 11 symptomatic carriers (age range 42-56; 8 females), and 23 matched non-carriers family members (age range 20-50; 13 females). We examined hippocampal volume ratio, CERAD Total Score, and CERAD Word List (i.e., Learning, Delayed Recall, and Recognition). Mann-Whitney U tests, Spearman correlations and regression models were conducted.
RESULTS
There were no differential associations between age, CERAD Total Score, CERAD Word List-Learning, Delayed Recall, Recognition, and hippocampal volume ratio in male and female carriers and non-carriers. Cognitively-unimpaired female carriers showed better CERAD Total scores and CERAD Word List-Learning than cognitively-unimpaired male carriers, despite having similar hippocampal volume ratios. The interaction of sex and hippocampal volume ratio did not predict cognitive performance across groups.
CONCLUSION
Our preliminary findings suggest that cognitively-unimpaired female carriers showed a verbal memory reserve, and as disease progresses, female carriers did not exhibit a cognitive susceptibility to AD-related neurodegeneration. Future studies with larger samples of autosomal dominant AD are warranted to further understand sex differences in AD-related clinical and pathological markers.
Identifiants
pubmed: 32925067
pii: JAD200723
doi: 10.3233/JAD-200723
pmc: PMC8075106
mid: NIHMS1695064
doi:
Substances chimiques
Biomarkers
0
PSEN1 protein, human
0
Presenilin-1
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1743-1753Subventions
Organisme : NIH HHS
ID : DP5 OD019833
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG054671
Pays : United States
Organisme : NIA NIH HHS
ID : F31 AG062158
Pays : United States
Références
Alzheimers Dement. 2018 Sep;14(9):1193-1203
pubmed: 29803541
Neurology. 2016 Apr 12;86(15):1368-1376
pubmed: 26984945
JAMA Netw Open. 2019 Oct 2;2(10):e1913909
pubmed: 31642932
JAMA Neurol. 2018 May 1;75(5):548-556
pubmed: 29435558
Lancet Neurol. 2012 Dec;11(12):1057-65
pubmed: 23137949
J Magn Reson Imaging. 2008 Apr;27(4):685-91
pubmed: 18302232
Neurology. 2016 Nov 1;87(18):1916-1924
pubmed: 27708128
Natl Vital Stat Rep. 2017 Apr;66(3):1-64
pubmed: 28437241
Front Neuroendocrinol. 2009 Jul;30(2):239-58
pubmed: 19427328
Neurology. 1993 Nov;43(11):2412-4
pubmed: 8232972
Acta Neuropathol. 2018 Dec;136(6):887-900
pubmed: 30334074
JAMA Neurol. 2015 Mar;72(3):316-24
pubmed: 25580592
Neurology. 2013 May 7;80(19):1778-83
pubmed: 23390181
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
J Int Neuropsychol Soc. 2019 Nov;25(10):1051-1060
pubmed: 31378214
JAMA Neurol. 2016 Apr;73(4):431-8
pubmed: 26902171
Neuroimaging Clin N Am. 2005 Nov;15(4):869-77, xi-xii
pubmed: 16443497
Alzheimers Dement. 2015 Mar;11(3):310-320
pubmed: 24418058
JAMA Neurol. 2020 May 1;77(5):632-642
pubmed: 32091549
JAMA Neurol. 2018 Aug 1;75(8):989-998
pubmed: 29801024
Arch Gen Psychiatry. 2005 Jun;62(6):685-91
pubmed: 15939846
JAMA Neurol. 2015 May;72(5):511-9
pubmed: 25775353
Am J Epidemiol. 2019 Jul 1;188(7):1224-1227
pubmed: 30824902
Lancet Neurol. 2011 Mar;10(3):213-20
pubmed: 21296022
Neurology. 2015 Apr 7;84(14):1433-42
pubmed: 25788555
JAMA Neurol. 2019 May 1;76(5):542-551
pubmed: 30715078
J Am Coll Cardiol. 2019 Sep 24;74(12):1543-1553
pubmed: 31537263
Alzheimers Res Ther. 2019 Dec 26;11(1):109
pubmed: 31878968
Brain Commun. 2020;2(1):fcaa025
pubmed: 32337508
J Prev Alzheimers Dis. 2019;6(2):112-120
pubmed: 30756118
Neurobiol Aging. 2018 Oct;70:308-324
pubmed: 29754747
Brain Imaging Behav. 2017 Feb;11(1):205-213
pubmed: 26843008
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Rev Neurol. 2007 Dec 1-15;45(11):655-60
pubmed: 18050096
Neurology. 2007 Sep 11;69(11):1074-83
pubmed: 17761551
Neuroimage. 1999 Feb;9(2):195-207
pubmed: 9931269